Hualan Biological Engineering (002007) H1 2025 earnings summary

Executive summary

• Revenue for H1 2025 reached ¥1.80 billion, up 8.80% year-over-year; net profit attributable to shareholders was ¥516 million, up 17.19% year-over-year.

• Blood products remained the core business, accounting for 96.57% of revenue; vaccine revenue grew 92.63% year-over-year.

• Cash dividend of ¥5 per 10 shares proposed, totaling ¥913.7 million, representing 177.13% of H1 net profit.

• R&D investment increased 10.69% year-over-year to ¥161 million, with multiple innovative drugs and vaccines advancing in clinical trials.

Financial highlights

• Operating income: ¥1.80 billion, up 8.80% year-over-year.

• Net profit attributable to shareholders: ¥516 million, up 17.19% year-over-year.

• Gross margin for blood products: 51.69%; for vaccines: 12.75%.

• Operating cash flow: ¥230.5 million, down 28.27% year-over-year.

• Total assets: ¥15.54 billion, down 4.75% from year-end 2024.

Outlook and guidance

• Focus remains on expanding blood plasma collection and maintaining leading market share in blood products.

• Continued investment in R&D for innovative drugs, mRNA vaccines, and new biologics.

• Company aims to enhance digitalization and operational efficiency, supporting high-quality growth.